InMed Pharmaceuticals Inc (INM) Fair Value & Analysis
Healthcare · US · Market cap $4.9M
InMed Pharmaceuticals Inc
INM · US
Fair value as of: Jul 17, 2026
From 1 valuation models · updated today
Share price +7.4% over the past month.
Price vs Fair Value (12 months)
12‑month range $0.6150 – $3.17 · fair‑value band $2.47 – $4.68 · the $1.59 price screens below the $3.75 fair value. As of Jul 17, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
InMed Pharmaceuticals Inc (INM) currently trades at $1.59, while our model-based Fair Value estimate is $3.75, implying the stock looks roughly 135.8% undervalued today. We read business quality at 32/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.
Trailing-twelve-month revenue stands at $4.9M. Revenue declined 26.2% year over year. The balance sheet holds a net cash position of $14.1M. Fundamentals as of Jul 17, 2026
Our scenario range runs from $2.47 (bear case) to $4.68 (bull case); at $1.59, the current price sits below that range. The share trades about 71% below its 52-week high and 177% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -49% fair-value upside, at 136%, INM screens cheaper than that median.
Key figures & financial health
More key figures
Figures from reported company fundamentals (EODHD) · as of Jul 17, 2026. TTM = trailing twelve months.
About the company
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment …
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
InMed Pharmaceuticals Inc reported revenue of $4.9M in FY2025 versus $0 in FY2021. Reported net income was −$8.2M in FY2025.
Is INM fairly valued? → Check now
Similar stocks
10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 17, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Hansoh Pharmaceutical Group 3692 | HK$29.32 | HK$23.94 | -18% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| PharmaEssentia Corporation 6446 | 1,160 TWD | 258.12 TWD | -78% |
| Torrent Pharmaceuticals Limited TORNTPHARM | ₹4,457 | ₹1,329 | -70% |
| Cipla Limited CIPLA | ₹1,377 | ₹628.39 | -54% |
| Zydus Lifesciences Limited ZYDUSLIFE | ₹1,089 | ₹841.98 | -23% |
| Dr. Reddy's Laboratories Limited DRREDDY | ₹1,278 | ₹595.34 | -53% |
| Lupin Limited LUPIN | ₹2,268 | ₹2,697 | +19% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is InMed Pharmaceuticals Inc (INM) undervalued?
What is the fair value of INM?
What is the quality score of INM?
What is the revenue of InMed Pharmaceuticals Inc (INM)?
What is the net profit margin of INM?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Tell me when InMed Pharmaceuticals Inc reaches its Fair Value
Just your email, and we'll notify you when the price and Fair Value of InMed Pharmaceuticals Inc materially change. Free bonus: the monthly Top-25 report of the most undervalued quality stocks.
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click. Not financial advice.
Not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.